Published in Int J Clin Pract on September 12, 2012
Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res (2013) 1.16
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res (2013) 0.99
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press) (2016) 0.87
Neurological Recovery in Two Patients with Cauda Equina Syndrome Secondary to L5 Lumbar Spine Giant Cell Tumour after Treatment with Denosumab without Surgery. Asian Spine J (2016) 0.79
A RANKL Wrinkle: Denosumab-Induced Hypocalcemia. J Med Toxicol (2016) 0.79
Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy. World J Surg Oncol (2014) 0.79
The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug. Biomed Res Int (2014) 0.78
Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice. Int J Womens Health (2016) 0.77
Denosumab: A bone antiresorptive drug. Med J Armed Forces India (2014) 0.76
Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma. Ann Transl Med (2016) 0.75
Denosumab: do we need another of the same? Int J Clin Pract (2012) 0.75
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. Springerplus (2016) 0.75
Can denosumab be a substitute, competitor, or complement to bisphosphonates? Korean J Pain (2017) 0.75
Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol (2017) 0.75
Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. Stem Cells Int (2016) 0.75
Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release (2016) 0.75
Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskelet Disord (2016) 0.75
Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. J Musculoskelet Neuronal Interact (2017) 0.75
Exercise and bone health across the lifespan. Biogerontology (2017) 0.75
Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature. Clin Rheumatol (2017) 0.75
Denosumab for treatment of immobilization-related hypercalcemia in a patient with end-stage renal disease. CEN Case Rep (2017) 0.75
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev (2000) 6.42
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Treatment of postmenopausal osteoporosis. Lancet (2002) 3.37
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
Bisphosphonates: from the laboratory to the clinic and back again. Bone (1999) 2.55
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Denosumab and bisphosphonates: different mechanisms of action and effects. Bone (2010) 2.37
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res (2010) 2.20
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab (2010) 1.68
The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int (2007) 1.64
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab (2011) 1.59
Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov (2002) 1.46
Assessment of fracture risk. Eur J Radiol (2009) 1.40
Population-based Canadian hip fracture rates with international comparisons. Osteoporos Int (2009) 1.36
Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can (2006) 1.33
Denosumab. Nat Rev Drug Discov (2010) 1.31
Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol (2011) 1.30
Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician (2011) 1.28
Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int (2003) 1.24
Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging (2011) 1.21
Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab (2001) 1.21
Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas (2007) 1.09
Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2004) 1.06
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone (2010) 0.96
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy (2010) 0.95
Clinical update on teriparatide. Curr Rheumatol Rep (2009) 0.93
Treatment of osteoporosis with denosumab. Maturitas (2010) 0.85
Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism. Endocrine (2009) 0.83
Denosumab (Prolia): A new option in the treatment of osteoporosis. Nurse Pract (2011) 0.81
Data from extension trials: denosumab and zoledronic acid. Curr Osteoporos Rep (2012) 0.79
New drugs: Denosumab, dienogest/estradiol valerate, and polidocanol. J Am Pharm Assoc (2003) (2010) 0.79
Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell (2001) 6.50
A nurse is suspended. BMJ (1996) 5.93
Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet (1997) 4.36
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell (1997) 3.71
Stringent spacing requirements for transcription activation by CRP. Cell (1990) 3.52
Genetic linkage map of human chromosome 7 with 63 DNA markers. Proc Natl Acad Sci U S A (1987) 2.91
The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med (1990) 2.89
Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol (1997) 2.76
Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum (2006) 2.73
Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int (2001) 2.67
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 2.51
N of 1 randomized trials for investigating new drugs. Control Clin Trials (1990) 2.37
Antibiotic uptake into gram-negative bacteria. Eur J Clin Microbiol Infect Dis (1988) 2.30
Assessment of a universal, school-based hepatitis B vaccination program. JAMA (1995) 2.23
Effects of brief counselling among male heavy drinkers identified on general hospital wards. Drug Alcohol Rev (1996) 2.23
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol (2001) 2.20
Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol (1999) 2.13
Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem (2000) 2.02
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Abnormalities identified in the knees of asymptomatic volunteers using peripheral magnetic resonance imaging. Osteoarthritis Cartilage (2005) 1.98
Multinational outbreak of Salmonella enterica serotype Newport infections due to contaminated alfalfa sprouts. JAMA (1999) 1.92
Musculoskeletal ultrasound training in rheumatology: the Belfast experience. Rheumatology (Oxford) (2005) 1.86
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
The role of two surface exposed loops in transcription activation by the Escherichia coli CRP and FNR proteins. Nucleic Acids Res (1991) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The osteoporosis care gap in Canada. BMC Musculoskelet Disord (2004) 1.81
Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum (1993) 1.80
Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology (2000) 1.79
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int (2012) 1.76
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol (1998) 1.72
The functional subunit of a dimeric transcription activator protein depends on promoter architecture. EMBO J (1994) 1.70
Predictive validity of the Readiness to Change Questionnaire. Addiction (1993) 1.65
Estimation of creatinine clearance in elderly persons in long-term care facilities. Am J Med (2001) 1.64
Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol (1997) 1.64
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Interactions between the Escherichia coli cyclic AMP receptor protein and RNA polymerase at class II promoters. Mol Microbiol (1993) 1.60
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1999) 1.60
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int (2000) 1.59
The structure and physiology of gastrointestinal mucus. Adv Exp Med Biol (1982) 1.59
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
Health and war in Congo-Brazzaville. Lancet (2000) 1.47
Long-term treatment of hypercholesterolemia with dietary fiber. Am J Med (1994) 1.47
A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol (2004) 1.46
Epidemic of malaria in north-eastern Kenya. Lancet (1998) 1.45
Osteoporosis knowledge and information needs in healthcare professionals caring for patients with fragility fractures. Orthop Nurs (2007) 1.43
The fractional shortening-velocity ratio: validation of a new echocardiographic Doppler method for identifying patients with significant aortic stenosis. J Am Coll Cardiol (1990) 1.43
Invited article: CO2 laser production of fused silica fibers for use in interferometric gravitational wave detector mirror suspensions. Rev Sci Instrum (2011) 1.42
Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev (2001) 1.42
Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Antimicrob Agents Chemother (1992) 1.41
Organized home care: an alternative to institutions. Inquiry (1972) 1.39
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
The burden of illness of osteoporosis in Canada. Osteoporos Int (2012) 1.34
High mortality in an internally displaced population in Ituri, Democratic Republic of Congo, 2005: results of a rapid assessment under difficult conditions. Glob Public Health (2006) 1.31
Comparison of promoter activities in Escherichia coli and Pseudomonas aeruginosa: use of a new broad-host-range promoter-probe plasmid. FEMS Microbiol Lett (1990) 1.31
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Low-level exposures to lead: the Sydney lead study. Dev Med Child Neurol (1989) 1.28
Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ (2001) 1.28
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab (2011) 1.27
Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax (2002) 1.27
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int (2010) 1.27
The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest (1993) 1.25
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Preoperative correlates of impaired wound healing after saphenous vein excision. J Thorac Cardiovasc Surg (1989) 1.24
Tuberculosis screening in migrants in selected European countries shows wide disparities. Eur Respir J (2006) 1.20
The effects of mosquito transmission and population bottlenecking on virulence, multiplication rate and rosetting in rodent malaria. Int J Parasitol (2005) 1.20
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2010) 1.19
Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) 1.19
Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int (2001) 1.18
Genetic analysis of multiplex rheumatoid arthritis families. Genes Immun (1999) 1.18
Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum (2006) 1.18
Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res (2003) 1.16
Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int (1999) 1.15
Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int (2004) 1.15
Pentamidine inhibits mitochondrial intron splicing and translation in Saccharomyces cerevisiae. RNA (2000) 1.15
Surface characteristics of Pseudomonas aeruginosa grown in a chamber implant model in mice and rats. Infect Immun (1989) 1.15
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int (2011) 1.13
HLA-DQ beta-chain polymorphism in HLA-DR4 haplotypes associated with rheumatoid arthritis. Lancet (1987) 1.13
Evaluation of facial expression in acute pain in cats. J Small Anim Pract (2014) 1.12
An automated segmentation approach for highlighting the histological complexity of human lung cancer. Ann Biomed Eng (2010) 1.11
Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int (2003) 1.11
Treatment of established bone loss after renal transplantation with etidronate. Transplantation (2001) 1.11
A family with attenuated familial adenomatous polyposis due to a mutation in the alternatively spliced region of APC exon 9. Hum Mutat (1998) 1.11
Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int (2008) 1.11
Controlled trial of acupuncture for disabling breathlessness. Lancet (1987) 1.10
Hsp-70 is closely associated with the transferrin receptor in exosomes from maturing reticulocytes. Biochem J (1995) 1.10
Osteoporosis risk perceptions among patients who have sustained a fragility fracture. Patient Educ Couns (2008) 1.09
Prevalence of HIV-1 and HIV-2 mixed infections in Côte d'Ivoire. Lancet (1992) 1.09
Hand arthritis in systemic lupus erythematosus: an ultrasound pictorial essay. Lupus (2006) 1.09
Controlled trial of new formulae for feeding low birth weight infants. Early Hum Dev (1986) 1.09
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 1.07
A trial of the effect of nimodipine on outcome after head injury. Acta Neurochir (Wien) (1991) 1.04
The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol (2000) 1.04
A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (1997) 1.04
Gymnastic training and bone density in pre-adolescent females. Med Sci Sports Exerc (1997) 1.04